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Honey is a common supplement widely be-lieved to alleviate symptoms of allergic rhini-tis (AR). Yet, evidence for this phenomenon 
is scarce. To our knowledge, only 2 previous studies 
have investigated the effect of ingestion of honey on 
symptoms of AR, and they have reported contradic-
tory results.1,2 The first, a case-control study found no 
significant improvement in allergic rhinoconjunctivitis 
symptoms between participants who ingested a table-
spoon a day of honey for a period of 30 weeks com-
pared with a placebo group.1 The second study found 
a strong correlation between oral presensitization with 
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BACKGROUND AND OBJECTIVES: The role of honey in the treatment of allergic rhinitis (AR) is controversial. 
We studied the complementary effect of ingestion of a high dose of honey, in addition to standard medications, 
on AR. 
DESIGN AND SETTINGS: Prospective randomized placebo-controlled study. Subjects were recruited from an 
otolaryngology clinic in 2 tertiary referral centers in the East coast of Peninsular Malaysia. The study period 
ranged from April 2010-April 2011.
METHODS: Forty AR patients were divided equally into a case group and a control group. All the subjects re-
ceived a daily dose of 10 mg of loratadine for 4 weeks. The case group ingested 1 g/kg body weight of honey 
daily in separate doses for the 4-week period. The control group ingested the same dose of honey-flavored corn 
syrup as placebo. AR symptoms were scored at the start, week 4, and week 8 of the study. 
RESULTS: There were no significant differences between the mean total symptom score of the case and the con-
trol groups at the start of the study. At week 4, both groups showed progressive improvement in the symptoms; 
at week 8, only the case group showed a continuous improvement in the symptom score. Only the group that 
ingested honey showed a significant improvement in individual AR symptoms. The improvement persisted for a 
month after the cessation of the treatment. 
CONCLUSION: Honey ingestion at a high dose improves the overall and individual symptoms of AR, and it 
could serve as a complementary therapy for AR.
local honey and improvement in rhinoconjuctival and 
other allergy symptoms in pollen allergy patients dur-
ing the subsequent pollen season.2 Both studies were 
conducted in countries with a seasonal climate. In many 
cultures and religions in Asia, honey has been utilized 
for healing purposes since ancient times.3-6 Despite be-
ing the largest continental producer of honey world-
wide,7 thus far, no study has been conducted in Asia’s 
tropical climate. 
We studied the complementary effect of ingestion of 
honey on AR, in addition to standard medication, in a 
randomized clinical setting. The study was conducted 
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in a multiracial tropical Asian population. In contrast 
to the previous published reports, this study utilized a 
different study methodology and different sets of study 
criteria, with much higher dosages of ingested honey. 
The reason for the higher dosages was because positive 
health effects of honey are only reportedly achieved if 
it is consumed at higher doses of 50 to 80 g per intake.8 
METHODS
Subjects were recruited from an otolaryngology clinic in 
2 tertiary referral centres in the East coast of Peninsular 
Malaysia. The data were collected over a 1-year period. 
The inclusion criteria comprised subjects aged above 
18 years, a diagnosis of AR using clinical history and 
positive skin prick test, and a willingness to consume 
a considerable amount of honey daily for the study pe-
riod. Subjects with known hypersensitivity to honey; a 
history of asthma, diabetes, or other chronic medical 
illnesses that require constant medical attention; a his-
tory of allergy desensitization for the past 5 years; and 
pregnancy were excluded from the study. The subjects’ 
demographic data were collected, together with their 
clinical history of allergy. All subjects underwent a skin 
prick test (ALK–Abello skin prick test kit, Bege Alle, 
2970 Horsholm, Denmark). The following 5 common 
allergens in the local community were used for the skin 
prick test: Dermatophagoides pteronyssinus (house 
dust mite), Felis domesticus (domestic cat), Mucor 
mucedo (fungi), wheat flour, and peanut. Histamine 
(as a positive control) and normal saline (as a nega-
tive control) were also included. The technique of the 
skin test followed previously described steps.9 The 
presence of a wheal and flare of at least 3 mm and 10 
mm larger than the negative control after 15 minutes 
was regarded as a positive reaction. The subjects with 
a negative skin prick test to any of the allergens were 
further excluded from the study. All the subjects were 
then graded according to the Allergic Rhinitis and Its 
Impact on Asthma (ARIA) classification.10
The subjects were randomly divided into 2 equal 
sized groups by a random number generator. All sub-
jects were treated with a second-generation antihista-
mine (loratidine, 10 mg once daily) from the begin-
ning of the study until 4 weeks. The case group was 
given honey and the control group received honey-
flavored corn syrup as placebo. They were instructed 
to ingest this at 1 g per kg of body weight per day in 
separate doses for 4 weeks (1 tablespoon=20 g). The 
type of honey used in this study was Tualang honey, 
a raw, unprocessed, multifloral honey harvested from 
beehives of the giant honey bee (Apis dorsata) built 
on the branches of giant trees named Tualang in the 
Malaysian rainforest. The corn syrup had the texture, 
color, and taste similar to the honey used. All subjects 
received the honey and the placebo in the same con-
tainer, in a double-blinded manner, whereby neither 
the research assistants nor the subjects knew what 
they were receiving. All subjects were instructed not to 
take any other honey or its products during the course 
of the study. Compliance was assessed by giving the 
subjects a diary in 4 stamped envelopes to record the 
dosage taken and possible side effects experienced in 
a week. The subjects were supposed to post the enve-
lopes together with the diary each week. The research 
assistants followed up with the participants through a 
telephone call when the envelopes were not received 
each week.
The initial symptom scores were recorded at the 
start of the study and repeated at day 28 (week 4) 
and day 56 (week 8). Seven symptoms were assessed 
in the symptom score: nasal blockage, rhinorrhea, hy-
posmia, nasal, eye and palatal itchiness, and sneezing. 
The scoring was done by asking the patient to evaluate 
the severity of individual symptoms using a 7-point 
visual analog scale, published by The Joint Task Force 
on Practice Parameters on Allergy, Asthma, and 
Immunology.11 The symptom score was marked by the 
same independent person at all times.
The sample size was calculated using Power 
Analysis and Sample Size, 11th edition (NCSS, 
Kaysville, Utah) software to an 80% power of study.
Data analysis
Symptoms of AR, a positive family history of AR, 
asthma history, and ARIA classification were recorded 
in binary dichotomous format (present or absent of 
outcomes). AR symptoms were assumed to be present 
when the subject reported a score of at least 3 (mild, 
easily tolerable symptoms) in the AR symptom score. 
The case and the control groups were compared with 
respect to the frequency of the dichotomous data us-
ing a chi-square analysis. The mean and the standard 
deviation were calculated for the total symptom score 
at the start of the study, week 4, and week 8 for the 
case and the control groups. Multiple comparison pro-
cedures using the repeated measures ANOVA and 
independent t test were used to determine the signifi-
cance of differences in the total symptoms score and in 
the individual symptoms score between the case and 
the control groups at the start, week 4 and week 8 of 
the study. 
The study protocol was approved by the Research 
and Ethics Committee of the hospitals where the study 
took place.
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RESULTS
Forty AR patients were recruited in this study and were 
divided randomly and equally into a case and a con-
trol group. The age group of the subjects in the entire 
study group ranged from 20 to 50 years, with a mean 
age of 35.7 years. The mean age of the control group 
was 33.2 years, and the mean age of the case group was 
38.2 years. A total of 26 female patients (65%) were 
included in the study, 12 of whom were in the con-
trol group. The majority of the study population was 
Malay, which accounted for 92.5% (37) of the subjects, 
followed by Chinese (5%) and one Siamese (2.5%). 
Most of the study subjects (25%) were teachers, fol-
lowed by housewives (20%), office workers (15%), and 
self-employed (5%) individuals. The remainder subjects 
were either odd-job workers or unemployed. The aver-
age rate of honey consumption prior to the study was 
equal in both the case and the control groups, with the 
average being 1 to 2 tablespoons a week. The majority 
of the subjects had non-seasonal AR (persistent type) 
based on the ARIA classification, with most having a 
severe type.
The clinical demography of the subjects is sum-
marized in Table 1. The prevalence of the symptoms, 
clinical history, severity, and positive skin prick test were 
equally distributed in the case and the control groups, 
with no significant difference between the groups 
(P>.05). Table 2 shows that there were no significant 
differences between the mean total symptom score of 
the case group and the control group at the start of the 
study. No significant differences were observed at week 
4 and week 8 between the case and the control groups.
One-way repeated measures ANOVA was con-
ducted to test the effect of ingestion of honey on the 
AR symptoms score before, within, and after the expo-
sure weeks. There was a significant effect of ingestion of 
honey on AR symptoms score, F(2.57)=6.159. Paired 
samples t tests were used to make post hoc compari-
sons between the weeks in the case and control groups, 
as shown in Table 3. Significant differences were ob-
served between the mean total symptom score at week 
0 and week 4, week 4 and week 8, and week 0 and week 
8 within the case group. This suggests that there was 
progressive amelioration of the symptoms from week 0 
to week 8 within the honey ingestion group. However, 
within the control group, the significant differences 
were observed at week 0 to week 4, but not from week 
4 to week 8. This suggests that the improvement in the 
symptoms declined from week 4 onward in this group 
following the cessation of the antihistamine treatment. 
The cardinal symptoms of AR are nasal blockage, 
nasal discharge, nasal itchiness, and sneezing. We found 
Table 1. Clinical characteristics of the study subjects.
Symptoms
Total subjects 
(n=40)
n (%)
Case (n=20)
n (%)
Control 
(n=20)
n (%)
P valueaPositive 
symptoms at 
the start of 
studyb
nasal itchiness 40 (100) 20 (100) 20 (100) >.05
nasal blockage 39 (97.5) 19 (95) 20 (100)
rhinorrhea 39 (97.5) 19 (95) 20 (100)
Sneezing 39 (97.5) 20 (100) 19 (95)
eye itchiness 38 (95) 18 (90) 20 (100)
Palate itchiness 35 (87.5) 18 (90) 17 (85)
hyposmia 34 (85) 17 (85) 17 (85)
family history 
of Ar 22 (55) 10 (50) 12 (60) .520
Concurrent asthma 15 (37.5) 10 (10) 5 (25) .102
AriA classification
Mild intermittent 8 (20) 3 (15) 5 (25) df=3, P=.876
Moderate-severe 
intermittent 4 (10) 2 (10) 2 (10)
Mild persistent 7 (17.5) 4 (20) 3 (15)
Moderate-severe 
persistent 21 (52.5) 11 (55) 10 (50)
Positive skin prick 
test
house dust mite 39 (97.5) 20 (100) 19 (95) >.05
Peanut 37 (92.5) 17 (85) 20 (100)
Cat 36 (90) 18 (90) 18 (90)
Wheat flour 34 (85) 19 (95) 15 (75)
Mucor mucedo 29 (72.5) 13 (65) 16 (80)
Ar: Allergic rhinitis, df: degree of freedom, aChi-square analysis of the difference between the case and control 
group. bPositive symptom is when the subject reported a score of at least 3 (mild, easily tolerable symptom).  
that these symptoms were the most common com-
plaints of the subjects in both groups (Table 1). These 
4 cardinal symptoms showed a significant improvement 
with time in the case group (Table 4). However, in the 
control group, no significant improvement was seen for 
nasal blockage and rhinorrhea at the end of the study. 
In the case group, all 4 symptoms showed an overall 
improvement from week 0 to week 4 when subjects 
were taking antihistamine, and the improvement in all 
the symptoms, except rhinorrhea, continued even after 
stopping the antihistamine. However, this was not evi-
dent in the control group where no significant improve-
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ment was observed during the treatment (week 0–4) 
or after the medication was stopped (week 4–8). Nasal 
itchiness and sneezing were the 2 commonest symp-
toms expressed by our patients. The results suggest 
that nasal itchiness and sneezing in the case group had 
a more significant and sustained recovery, even after the 
treatment was stopped in the fourth week of the study 
compared with the control group.
DISCUSSION
We found that the ingestion of honey at high doses, in 
addition to the usual standard medication, affected the 
recovery of the symptoms of AR in our patients com-
pared with the control group. Those patients who in-
gested a regular daily high dose of honey exhibited signif-
icant alleviation of their overall symptoms, as shown by 
the improvement in the mean total symptom score. The 
case subjects also showed a progressive, steady improve-
ment in their overall mean symptom score throughout 
the study period from week 0 to week 8, whereas in the 
control subjects, the improvement in symptoms seemed 
to decline following the cessation of the antihistamine. 
The ingestion of honey at a high dose, together with the 
antihistamine, also significantly improved all 4 cardinal 
symptoms of AR, but the same effect was not seen in 
the control group. Although sneezing and nasal itchi-
ness improved significantly from week 0 to week 8 in 
both groups, the improvement after the withdrawal of 
antihistamine was significant only in those who had in-
gested honey.
In our study population, the main symptom ex-
pressed by the patients was nasal itchiness, followed 
by sneezing, runny nose and nasal blockage. Based on 
the ARIA classification, the majority of our patients 
had moderate-to-severe persistent AR. This is consis-
tent with the findings of a larger prevalence study on 
AR in the same population and geographical area.12 
We found no significant difference in the mean of the 
initial symptom score between the 2 groups, and this 
suggests satisfactory randomized sampling for subse-
quent comparisons. Based on the ARIA guidelines and 
the latest review of the safety of antihistamines, a sec-
ond-generation oral antihistamine, such as loratadine, 
is the first treatment option for AR.13,14 The develop-
ment of subsensitivity after prolonged treatment with 
certain antihistamines has been reported previously but 
not with loratadine.15,16 Both the case and the control 
groups showed a significant improvement from week 0 
to week 4 when antihistamine was taken. The ingestion 
of honey seemed to complement and sustain the effect 
of loratadine, which was not seen in the control group. 
Loratadine has been proven to be effective in reliev-
ing nasal itchiness, rhinorrhea, and sneezing in AR, but 
it provides only partial relief from nasal congestion.17 
In this study, the ingestion of honey, together with the 
antihistamine treatment, significantly improved all the 
4 symptoms, including nasal congestion. This study also 
showed that all 4 cardinal symptoms of AR showed 
more of an improvement within the first 4 weeks in 
those with honey ingestion. These results may indicate 
that the ingestion of honey as an adjuvant to antihis-
tamine improves the overall symptom score and indi-
vidual symptoms compared with the placebo within a 
short period. The effect sustained at one month after 
withdrawing the antihistamine treatment.
We postulate several mechanisms that possibly ex-
plain the improvement in the symptoms of AR with 
honey ingestion. First, honey could have suppressed an 
IgE-mediated hypersensitivity reaction in these sub-
jects. Several animal studies have indicated the immu-
nosuppressive activity of honey. For example, in mice, 
ovalbumin-specific IgE antibody responses elicited 
Table 2. Mean total symptoms score between case and control group at the start (week 0), week 4 and week 8 of the study.
Week Group
Total symptoms 
score
Mean (SD)
t test for equality 
of means (Equal 
variances 
assumed)
df P value
Week 0  Case 17.2 (3.64)
t=0.74 38 .464
Control 16.3 (4.45)
Week 4 Case 14.2 (4.85)
t=0.00 38 1.00
Control 14.2 (4.87)
Week 8              Case 11.9 (5.66)
t=0.8 38 .428
Control 13.1 (4.28)
df: degree of freedom, SD: standard deviation
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Table 3. Comparison of the mean total symptom score between week 0 & week 4, week 4 & week 8, and week 0 & week 8 within the case and the control 
group.
Week
Case Control
Differences of the 
total symptoms 
score between the 
weeks. 
Mean(SD)
t test
(df 19) P value
Differences of the 
total symptoms 
score between the 
weeks. 
Mean(SD)
t test
(df 19) P value
0-4 3.05 (4.76) t=2.86 .010 2.10 (4.15) t=2.26 .036
4-8 2.30 (3.28) t=3.14 .005 1.03 (3.54) t=1.30 .209
0-8 5.35 (4.98) t=4.81 .000 3.13 (4.10) t=3.41 .003
df: degree of freedom, SD: standard deviation
Table 4. Comparisons of the improvement of the mean symptoms score of the 4 cardinal symptoms of allergic rhinitis (nasal itchiness, sneezing, rhinorrhea & 
nasal blockage) in the case and the control group.
Symptoms Week
Case Control
Mean different 
of symptom 
score (SD)
t test, df 19 P value
Mean different 
of symptom 
score (SD)
t test, df 19 P value
nasal itchiness
0-4 0.45(0.95) t=2.13 .046 0.45(1.19) t=1.69 .107
4-8 0.30(0.47) t=2.85 .010 0.10(0.64) t=0.70 .494
0-8 0.75(0.97) t=3.47 .003 0.55(0.94) t=2.60 .017
Sneezing
0-4 0.48(0.88) t=2.33 .031 0.23(0.84) t=1.20 .244
4-8 0.32(0.89) t=2.13 .047 0.18(0.54) t=1.61 .124
0-8 0.80(1.32) t=2.43 .025 0.41(0.74) t=2.15 .045
nasal blockage
0-4 0.42(0.95) t=2.17 .043 0.19(0.44) t=1.62 .121
4-8 0.39(0.78) t=2.20 .04 0.39(0.87) t=1.80 .087
0-8 0.81(1.11) t=2.52 .021 0.58(1.01) t=1.65 .115
rhinorrhea
0-4 0.38(0.44) t=1.97 .063 0.56(0.78) t=2.07 .052
4-8 0.25(0.49) t=1.67 .112 0.14(0.38) t=1.56 .135
0-8 0.63(0.72) t=2.16 .044 0.70(0.72) t=1.87 .077
SD:standard deviation, df:degree of freedom
against different allergens were found to be completely 
suppressed by different sources of commercial honey.18 
Other animal studies showed the anti-allergic mecha-
nism of honey involves the inhibition of IgE-mediated 
mast cell activation both in vivo and in vitro.19,20 In an-
other study, royal jelly, a principal food of the queen 
bee, suppressed antigen-specific IgE production and 
histamine release from mast cells, restored macrophage 
function, and improved Th1/Th2 cell responses, result-
ing in the suppression of allergic reactions in mice.21 
Although evidence from human studies is still lack-
ing, a study involving patients with allergic fungal rhi-
nosinusitis provided evidence that the patients gained 
symptomatic benefits from topical application (spray) 
of manuka honey into the nose.22 The authors found 
that the patients with a better response had higher IgE 
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levels in their blood, pointing to the potential suppres-
sion of an IgE-mediated hypersensitivity reaction.
Second, it is possible that the introduction of honey 
into the body may have induced low-dose oral toler-
ance to these aeroallergens. Exposure to a constant low 
dose of the allergen (honey) may have made the body 
accustomed to its presence (tolerance) and decreased 
the chance of an overwhelming immune system re-
sponse such as an anaphylactic reaction when exposed 
to the same aeroallergen. Saarinen et al showed that 
the oral desensitization of an aeroallergen resulted in 
a less severe form of rhinitis and that the use of anti-
allergy medications was reduced in such orally desen-
sitized patients compared with a control group.2 There 
is evidence that early exposure in life to environmental 
and food allergens reduces the subsequent risk of al-
lergic diseases by developing tolerance.23-25 The balance 
between allergy and tolerance is dependent on regula-
tory T-cells.26 In healthy individuals, intact functional 
allergen-specific regulatory T-cells induce tolerance as 
a normal immunological response to allergens, but this 
response is impaired in allergic sufferers.26
Thirdly, honey has been reported to have an anti-in-
flammatory property.27,28 AR is an inflammatory disease 
resulting from an allergic cascade, which is characterized 
by inflammation of the mucosa surface, leading to stasis 
of mucus secretion, blockages of the airway, and, later 
on, the sinuses. In our case, the complementary effect of 
honey on the improvement in the symptom score may 
be attributable to the direct anti-inflammatory proper-
ty of honey, rather than the anti-allergy effect. We gave 
the antihistamine to both groups because it is useful in 
relieving the allergic symptoms of itchiness, sneezing, 
and rhinorrhea, but less so in relieving the nasal block-
age.17 The improvement in nasal blockage with honey 
ingestion was possibly mediated by the reduction in na-
sal inflammation, thereby opening up the nasal airway. 
Finally, in addition to the high sugar content, the type of 
honey used in this study contained, on average, higher 
amounts of antioxidants, including phenolic acids and 
flavonoids.29,30 According to a comprehensive review 
article of available epidemiological, animal, molecular, 
and immunological data, there are potentially benefi-
cial associations between combinations of antioxidant 
supplements and allergic diseases.31 However, the exact 
mechanism for the associations remains unclear.
Rajan et al found that subjects who ingested hon-
ey did not experience relief from their symptoms in 
excess of that seen in a placebo group.1 Our study dif-
fered from theirs in terms of the study population, 
the environment, and the study methodology. We used 
higher honey dosages and administered standard anti-
histamine treatment to all the patients in the case and 
the control groups. Repeated exposure to antigens is a 
prerequisite for the development of tolerance. In our 
study, higher dosages of honey may have increased the 
development of tolerance, possibly via T-cell anergy.32 
Standardizing the treatment in both groups, regardless 
of the symptoms, should have eliminated the potential 
biases from over- or under-treating AR with the usual 
standard medications. The timing of the exposure to 
the allergen may also have influenced the results of our 
study. The study by Rajan et al was conducted only dur-
ing the pollen season. Another similar study of honey 
ingested constantly during 5 pre-seasonal months 
showed a different outcome in the improvements of AR 
symptoms.2
We found that the high dose of honey ingestion is 
beneficial and that it appears to improve the symptoms 
of AR, at least, for a short duration. Determining the 
potential long-term effect of honey ingestion is beyond 
the scope of this study. However, these findings should 
be considered preliminary, as there are several limita-
tions of this study. Firstly, we used clinical criteria to 
determine symptoms severity, which can be subjec-
tive. Although we limited this potential bias by using 
a validated scoring instrument and employing an in-
dependent assessor to conduct the symptom score, an 
immunological test would be more objective. Work is 
currently under way to study the potential relationship 
between honey ingestion and the amelioration of the 
symptoms of AR using objective molecular analysis. 
The honey used in this study was a raw, unprocessed 
one and not a standardized commercially manufac-
tured honey. Therefore, the results are only applicable 
to the batches of honey used here. The sample size of 
this study is relatively small; hence, further evidence in a 
larger randomized-controlled trial is needed to validate 
the results.
In conclusion, we found that the ingestion of high 
dose of honey had a significant complementary effect in 
improving the overall symptoms in AR patients com-
pared to the placebo. The result indicates that honey 
could serve as a complementary therapy for AR.
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